Status:
RECRUITING
PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Lead Sponsor:
University Health Network, Toronto
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles t...
Detailed Description
RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from ...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
- Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
- A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
- Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).
Exclusion
- Contraindication for MR as per current institutional guidelines.
- Contraindication for Gadolinium injection as per current institutional guidelines.
- Inability to lie supine for at least 45 minutes.
- Any patient who is pregnant or breastfeeding.
- Any patient with known hypersensitivity to 18F-FDG.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04901884
Start Date
June 1 2021
End Date
June 1 2026
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2M9